Natural Capsules

Natural Capsules Debt/EBITDA

The Total Debt to EBITDA Ratio of Natural Capsules (524654.BO) as of Nov 7, 2026 is 6.05. In the previous year, Total Debt to EBITDA Ratio was 5.80 — a change of 4.19% (higher).

Debt/EBITDA

6.05

YoY

4.19%

Last updated:

Total Debt to EBITDA Ratio of Natural Capsules is 2025 6.05 . Total Debt to EBITDA Ratio of Natural Capsules was 2024 5.80 . It decreases by 4.19% higher compared to the previous year.

The Natural Capsules Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2018
0.00 INR
Jan 1, 2019
1.10 INR
Jan 1, 2020
1.18 INR
Jan 1, 2021
0.88 INR
Jan 1, 2022
2.01 INR
Jan 1, 2023
2.76 INR
Jan 1, 2024
5.80 INR
Jan 1, 2025
6.05 INR
The Natural Capsules Debt/EBITDA history
YEARDebt/EBITDAYoY
6.05+4.19%
5.80+110.06%
2.76+37.19%
2.01+128.47%
0.88-25.34%
1.18+6.87%
1.10—
0.00-100.00%
0.59+1.82%
0.58+21.91%
0.48-13.59%
0.55—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Natural Capsules Stock analysis

What does Natural Capsules do? Natural Capsules Ltd. manufactures hard gelatin capsule shells, hard cellulose capsule shells, and pharmaceutical dosage forms in capsule dosage form. The company offers specialized products including BSE/TSE-free gelatin capsule shells, shiny gelatin capsule shells, SLS-free gelatin capsule shells, halal certified gelatin capsule shells, fortified gelatin capsule shells, sweet gelatin capsule shells, fast release gelatin capsule shells, printed gelatin/cellulose capsule shells, vegetarian capsule shells, and enteric capsule shells. These capsules are sold to the pharmaceutical and dietary supplement industries both domestically and internationally. The company provides turnkey solutions to all customers, focusing on manufacturing hard capsules for these sectors. Natural Capsules Ltd. generates revenue through the sale of its diverse capsule product range to pharmaceutical and dietary supplement companies. The firm's manufacturing units in Bangalore and Pondicherry produce all types of hard capsules, including gelatin and cellulose-based options, catering to specific industry needs such as halal certification, BSE/TSE-free standards, and vegetarian requirements. Domestic sales and exports to various countries form the primary market segments for the company's products. The company's product portfolio targets pharmaceutical manufacturers requiring high-quality capsule shells and dietary supplement producers seeking specialized formulations. Customers include firms in the pharmaceutical industry needing BSE/TSE-free or halal-certified capsules, as well as dietary supplement companies looking for vegetarian or fast-release options. All products are manufactured at the Bangalore and Pondicherry facilities and distributed through direct sales channels to meet customer specifications. Natural Capsules is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Natural Capsules stock

Total Debt to EBITDA Ratio of Natural Capsules is 6.05 in 2025.

Total Debt to EBITDA Ratio of Natural Capsules changed from 5.80 to 6.05, representing a 4.19% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Natural Capsules since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Natural Capsules with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Natural Capsules

All Key Metrics — Natural Capsules